Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments

Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments

The BNT162b2 vaccine is globally used for preventing morbidity and mortality related to COVID-19. Cancer patients have had priority for receiving the vaccine due to their diminished immunity. This study reports the response rate of administering the third and fourth vaccine doses to cancer patients...

Full description

Bibliographic Details
Main Authors: Abed Agbarya, Ina Sarel, Tomer Ziv-Baran, Orna Schwartz, Yelena Shechtman, Ella Kozlener, Rasha Khoury, Mohammad Sheikh-Ahmad, Leonard Saiegh, Forat Swaid, Asala Abu Ahmad, Urska Janzic, Ronen Brenner
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Diseases
Subjects:
SARS-CoV-2
BNT162b2 vaccine
cancer patients
anti-neoplastic treatment
chemotherapy
antibodies
Online Access:https://www.mdpi.com/2079-9721/11/4/128

Similar Items

Similar Items